Professor Henrik Grönberg is awarded the Swedish Cancer Foundation’s Cancer Researcher of the Year 2022 for his research that enables early detection of prostate cancer. Henrik Grönberg’s research has led to the test Stockholm3.
The Cancer Foundation’s research committee, chaired by former chairman of the Nobel Committee, Klas Kärre, gave the following justification:
“For world-leading research on prostate cancer. For methods of detecting prostate cancer at an early stage, but also to avoid unnecessary examinations, as well as to identify the patients who need to be treated immediately. All this contributes to more individualized treatment, increased chance of cure and high quality of life.”
“I am very happy and honored to get this award. Prostate cancer is the most common and deadliest form of cancer for men in Sweden. Unfortunately, 2,300 men in Sweden alone still die every year. We now have the tools to introduce general screening, which would significantly reduce mortality from the disease,” said Professor Grönberg.
“The award from the Swedish Cancer Foundation shows the great value that Stockholm3 adds through earlier detection of prostate cancer and by simultaneously reducing unnecessary treatments. This award follows last summer’s award for best abstract in oncology at the European Association of Urology. We are very proud of these national and international awards, which are also important milestones in our work to establish Stockholm3 globally and radically improve the precision in prostate cancer diagnostics,” said David Rosén, CEO of A3P Biomedical.
Henrik Grönberg is a professor of cancer epidemiology at Karolinska Institutet and a senior physician. Henrik is a co-founder of A3P Biomedical and a leading expert in prostate cancer. Since 2005, Henrik has been a professor at Karolinska Institutet, where he leads a research group with 35 researchers focused on prostate cancer. He is also responsible for the Prostate Cancer Center at Capio S:t Göran’s Hospital in Stockholm.
For additional information, please contact:
David Rosen, CEO
telephone: +46 73 268 6612
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).
Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).
Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers also benefit from direct cost savings of 17 to 28 percent (1).
About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. In 2020, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported by GLOBOCAN. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.
About A3P Biomedical, www.a3pbiomedical.com
A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden.